Evidence map›Paper›PMID 36341411›Full record

ReviewFrontiers in immunology2022

Solute carrier nutrient transporters in rheumatoid arthritis fibroblast-like synoviocytes.

Alyssa Torres, Brian Pedersen, Monica Guma

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Genome-Wide Association Analysis of Heat Tolerance in FInternational journal of molecular sciences · 2023
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Alyssa TorresDivision of Rheumatology, Allergy and Immunology and School of Medicine, University of California, San Diego, San Diego, CA, United States.
Brian PedersenDivision of Rheumatology, Allergy and Immunology and School of Medicine, University of California, San Diego, San Diego, CA, United States.
Monica GumaDivision of Rheumatology, Allergy and Immunology and School of Medicine, University of California, San Diego, San Diego, CA, United States.
University of California, San Diego · USVA San Diego Healthcare System · US

Funding

Targeting hexokinase-2 in rheumatoid arthritisR01AR073324 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GUMA, MONICA · 2018 to 2022
$2.4M
NIAMS NIH HHS R01 AR073324
6 · The paper itself

Abstract

Metabolomic studies show that rheumatoid arthritis (RA) is associated with metabolic disruption. Metabolic changes in fibroblast-like synoviocytes (FLS) likely contribute to FLS abnormal response and strongly contribute to joint destruction. These changes often involve increased expression of nutrient transporters to meet a high demand for energy or biomolecules. The solute carrier (SLC) transporter families are nutrient transporters and serve as 'metabolic gates' for cells by mediating the transport of several different nutrients such as glucose, amino acids, vitamins, neurotransmitters, and inorganic/metal ions. In RA FLS SLC-mediated transmembrane transport was one pathway associated with different epigenetic landscape between RA and osteoarthritis (OA) FLS. These highlight that transporters from the SLC family offer unique targets for further research and offer the promise of future therapeutic targets for RA.

Indexed as

Arthritis, RheumatoidOsteoarthritisSynoviocytesFibroblastsHumansNutrientsNutrientsFLSmetabolismnutrientsRASLC transporters

Identifiers

PMID36341411
PMCPMC9632162
OpenAlexW4306874540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.